Growth of Value-Based Purchasing and Contracting for Cell & Gene Therapies Part 2
The Self-Insurer • Fri Apr 04 2025
As research and development of these cutting-edge therapies rapidly progress, employers have an opportunity to explore and implement cost-effective approaches for making these therapies available to employees and covered dependents who need them. Strategies include paying over time, negotiating rebates based on the therapy’s effectiveness and buying stop-loss insurance.
Improving Access and Affordability Without Bankrupting the Health Plan
As research and development of these cutting-edge therapies rapidly progress, employers have an opportunity to explore and implement cost-effective approaches for making these therapies available to employees and covered dependents who need them. Strategies include paying over
time, negotiating rebates based on the therapy’s effectiveness and buying stop-loss insurance.
Read the full article on page 4 here: April 2025 The Self-Insurer by The Self-Insurer Magazine
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.